Bulur, IşılBülbül Başkan, EmelÖzdemir, MustafaBalevi, AliKocatürk Göncü, EmekKıvanç Altunay, İlknurGönül, MüzeyyenErgin, CanErtam, İlgenKaya Erdo?an, HilalBilgin, MuzafferErdem, Mustafa Teoman10.07.20192019-07-1010.07.20192019-07-102018Bulur, I., Bülbül Başkan, E., Özdemir, M., Balevi, A., Kocatürk Göncü, E., Kıvanç Altunay, İ. ... Erdem, M. T. (2018). The efficacy and safety of omalizumab in refractory chronspontaneous urticaria: Real-life experience in Turkey. Acta Dermatovenerologica Alpina, Pannonica et Adriatica, 27(3), 121-126. https://dx.doi.org/10.15570/actaapa.2018.251318-44581581-2979https://hdl.handle.net/20.500.12511/1120https://dx.doi.org/10.15570/actaapa.2018.25Introduction: This study used real-world data to evaluate the effectiveness and reliability of omalizumab in treating recalcitrant chronic spontaneous urticaria in Turkish patients. Methods: Study data were collected retrospectively from eight tertiary-care hospitals in Turkey. This study included 132 patients with chronic spontaneous urticaria that were resistant to H1 antihistamine treatment in a dose up to four times the licensed dose and were treated with 300 mg/month of omalizumab for 6 months. Results: The mean weekly urticarial activity score (UAS7) after omalizumab treatment improved significantly compared to the pretreatment score (p <0.001). Treatment response was detected primarily in the 1st and 2nd months after treatment. No significant association was observed between omalizumab’s treatment effectiveness and disease-related parameters or laboratory data. The mean dermatology life quality index was 23.12 ± 6.15 before treatment and decreased to 3.55 ± 3.60 6 months after treatment (p <0.001). No side effects were reported in 89.4% (118) of the patients. Conclusion: This study showed that UAS7 decreased significantly and quality of life improved in omalizumab-treated patients. Moreover, treatment effectiveness was mainly observed in the first 2 months after treatment. However, no association was observed between omalizumab treatment effectiveness and disease-related parameters or laboratory data.eninfo:eu-repo/semantics/openAccessChronic Spontaneous UrticariaDermatology Life QualityOmalizumabSide EffectUAS7Article27312112610.15570/actaapa.2018.25N/AN/A